Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) have been given an average rating of “Buy” by the eight brokerages that are currently covering the firm. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $20.00.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $23.00 target price (up from $22.00) on shares of Amphastar Pharmaceuticals in a research report on Wednesday, September 7th. BMO Capital Markets assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, June 28th. They issued a “market perform” rating and a $17.00 target price for the company. Needham & Company LLC increased their target price on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Finally, Jefferies Group increased their target price on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th.

In related news, CFO William J. Peters sold 2,297 shares of the firm’s stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $17.76, for a total transaction of $40,794.72. Following the completion of the sale, the chief financial officer now directly owns 64,652 shares in the company, valued at $1,148,219.52. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jack Y. Zhang sold 444,199 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $21.03, for a total transaction of $9,341,504.97. Following the sale, the chief executive officer now owns 1,295,685 shares of the company’s stock, valued at $27,248,255.55. The disclosure for this sale can be found here. Corporate insiders own 29.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC boosted its stake in Amphastar Pharmaceuticals by 1.4% in the second quarter. ProShare Advisors LLC now owns 37,737 shares of the company’s stock valued at $608,000 after buying an additional 524 shares during the last quarter. American International Group Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 10.1% in the second quarter. American International Group Inc. now owns 20,489 shares of the company’s stock worth $330,000 after buying an additional 1,882 shares in the last quarter. Strs Ohio boosted its stake in shares of Amphastar Pharmaceuticals by 5.3% in the second quarter. Strs Ohio now owns 47,900 shares of the company’s stock worth $772,000 after buying an additional 2,400 shares in the last quarter. Acrospire Investment Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock worth $109,000 after buying an additional 2,479 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Amphastar Pharmaceuticals by 11.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 26,305 shares of the company’s stock worth $424,000 after buying an additional 2,637 shares in the last quarter. Hedge funds and other institutional investors own 35.87% of the company’s stock.

Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 18.425 on Monday. The company’s 50 day moving average is $19.26 and its 200-day moving average is $16.18. The stock has a market capitalization of $831.35 million, a PE ratio of 59.821 and a beta of 1.83. Amphastar Pharmaceuticals has a 1-year low of $10.50 and a 1-year high of $21.53.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Monday, August 8th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.22. The business had revenue of $68 million for the quarter, compared to the consensus estimate of $62.10 million. Amphastar Pharmaceuticals had a net margin of 5.19% and a return on equity of 4.71%. The company’s revenue was up 26.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.09) earnings per share. Analysts forecast that Amphastar Pharmaceuticals will post $0.37 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

5 Day Chart for NASDAQ:AMPH

Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.